Schmitt Volker H, Billaudelle Anna-Maria, Schulz Andreas, Keller Karsten, Hahad Omar, Tröbs Sven-Oliver, Koeck Thomas, Michal Matthias, Schuster Alexander K, Toenges Gerrit, Lackner Karl J, Prochaska Jürgen H, Münzel Thomas, Wild Philipp S
Department of Cardiology, Cardiology I, University Medical Center, Johannes Gutenberg University Mainz, 55131 Mainz, Germany.
German Center for Cardiovascular Research (DZHK), Partner Site Rhine-Main, 55131 Mainz, Germany.
J Clin Med. 2021 Aug 27;10(17):3851. doi: 10.3390/jcm10173851.
This study sought to investigate the prevalence and clinical outcome of left ventricular (LV) geometry in prediabetes and type 2 diabetes mellitus (T2DM) and the impact of glucose metabolism on the incidence of left ventricular hypertrophy (LVH).
15,010 subjects (35-74 years) of the population-based Gutenberg Health Study were categorized into euglycemia, prediabetes, and T2DM according to clinical and metabolic (HbA1c) information. Clinical outcome was assessed via structured follow-up.
The study comprised 12,121 individuals with euglycemia (81.6%), 1415 with prediabetes (9.5%), and 1316 with T2DM (8.9%). Prevalence of LVH increased from euglycemia (10.2%) over prediabetes (17.8%) to T2DM (23.8%). Prediabetes and T2DM were associated with increased LV mass index (prediabetes: β1.3 (95% CI 0.78-1.81), < 0.0001; T2DM: β2.37 (95% CI 1.81; 2.92), < 0.0001) independent of age, sex, and cardiovascular risk factors (CVRF). The frequency of LVH was related to the presence of T2DM (prevalence ratio (PR)T2DM 1.2 (95% CI 1.06-1.35), = 0.0038). T2DM was related to mortality independent of age, sex, and CVRF regardless of LVH (hazard ratio (HR)T2DM-LVH 2.67 (95% CI 1.94-3.66), < 0.0001; HRT2DM-noLVH 1.59 (95% CI 1.29-1.96), < 0.0001), prediabetes was only associated with outcome in individuals with LVH independent of age and sex (HRprediabetes-LVH 1.51 (95% CI 1.01-2.25), = 0.045). Neither T2DM nor prediabetes were predictors of incident LVH after adjustment for clinical covariates.
Prediabetes and T2DM promote alterations of cardiac geometry. T2DM and particularly the coprevalence of T2DM with LVH substantially reduce life expectancy. These findings highlight the need for new therapeutic and screening approaches to prevent and detect cardiometabolic diseases at an early stage.
本研究旨在调查糖尿病前期和2型糖尿病(T2DM)患者左心室(LV)几何形态的患病率及临床结局,以及糖代谢对左心室肥厚(LVH)发生率的影响。
基于古登堡健康研究的15010名受试者(35 - 74岁),根据临床和代谢(糖化血红蛋白)信息分为血糖正常、糖尿病前期和T2DM组。通过结构化随访评估临床结局。
该研究包括12121名血糖正常个体(81.6%)、1415名糖尿病前期个体(9.5%)和1316名T2DM个体(8.9%)。LVH的患病率从血糖正常组(10.2%)经糖尿病前期组(17.8%)升至T2DM组(23.8%)。糖尿病前期和T2DM与左心室质量指数增加相关(糖尿病前期:β1.3(95%可信区间0.78 - 1.81),P < 0.0001;T2DM:β2.37(95%可信区间1.81 - 2.92),P < 0.0001),且独立于年龄、性别和心血管危险因素(CVRF)。LVH的发生频率与T2DM的存在相关(患病率比(PR)T2DM 1.2(95%可信区间1.06 - 1.35),P = 0.0038)。无论是否存在LVH,T2DM均与死亡率独立相关,且独立于年龄、性别和CVRF(风险比(HR)T2DM - LVH 2.67(95%可信区间1.94 - 3.66),P < 0.0001;HR T2DM - noLVH 1.59(95%可信区间1.29 - 1.96),P < 0.0001),糖尿病前期仅在独立于年龄和性别的LVH个体中与结局相关(HR prediabetes - LVH 1.51(95%可信区间1.01 - 2.25),P = 0.045)。调整临床协变量后,T2DM和糖尿病前期均不是新发LVH的预测因素。
糖尿病前期和T2DM会促进心脏几何形态改变。T2DM,尤其是T2DM与LVH并存,会显著降低预期寿命。这些发现凸显了需要新的治疗和筛查方法,以便在早期预防和检测心脏代谢疾病。